Douglas J. Biedenbach
About
Douglas J. Biedenbach is a scholar working on Molecular Medicine, Pharmacology and Epidemiology.
According to data from OpenAlex, Douglas J. Biedenbach has authored 153 papers receiving a total of 6.1k indexed citations (citations by other indexed papers that have themselves been cited), including 93 papers in Molecular Medicine, 72 papers in Pharmacology and 69 papers in Epidemiology. Recurrent topics in Douglas J. Biedenbach's work include Antibiotic Resistance in Bacteria (93 papers), Antibiotics Pharmacokinetics and Efficacy (70 papers) and Antimicrobial Resistance in Staphylococcus (58 papers). Douglas J. Biedenbach is often cited by papers focused on Antibiotic Resistance in Bacteria (93 papers), Antibiotics Pharmacokinetics and Efficacy (70 papers) and Antimicrobial Resistance in Staphylococcus (58 papers). Douglas J. Biedenbach collaborates with scholars based in United States, Brazil and Australia. Douglas J. Biedenbach's co-authors include Ronald N. Jones, Gary J. Moet, Thomas R. Fritsche, Daniel F. Sahm, Krystyna M. Kazmierczak, Meredith Hackel, Hélio S. Sader, Samuel K. Bouchillon, Robert E. Badal and Michael A. Pfaller and has published in prestigious journals such as Journal of Clinical Microbiology, Antimicrobial Agents and Chemotherapy and Journal of Antimicrobial Chemotherapy.
In The Last Decade
Douglas J. Biedenbach
151 papers receiving 5.7k citations
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Douglas J. Biedenbach United States | 44 | 2.9k | 2.2k | 2.0k | 1.9k | 1.8k | 153 | 6.1k | ||
| Stephen G. Jenkins United States | 45 | 3.1k 1.1× | 1.7k 0.8× | 2.3k 1.2× | 1.3k 0.7× | 1.9k 1.1× | 152 | 6.3k | ||
| Teresa Spanu Italy | 43 | 3.5k 1.2× | 1.4k 0.7× | 2.3k 1.1× | 1.4k 0.8× | 1.8k 1.0× | 130 | 6.5k | ||
| Joseph W. Chow United States | 38 | 1.9k 0.7× | 3.1k 1.4× | 1.7k 0.9× | 1.0k 0.5× | 1.9k 1.1× | 74 | 6.1k | ||
| Mario Tumbarello Italy | 52 | 3.8k 1.3× | 2.8k 1.3× | 3.5k 1.8× | 1.9k 1.0× | 1.8k 1.0× | 155 | 8.4k | ||
| David M. Shlaes United States | 47 | 2.6k 0.9× | 2.6k 1.2× | 1.9k 1.0× | 1.5k 0.8× | 1.5k 0.8× | 131 | 8.0k | ||
| Romney M. Humphries United States | 48 | 2.8k 1.0× | 2.1k 1.0× | 1.5k 0.8× | 1.3k 0.7× | 2.0k 1.1× | 232 | 6.8k | ||
| Philippe Lagacé‐Wiens Canada | 38 | 2.9k 1.0× | 1.3k 0.6× | 1.7k 0.9× | 1.8k 1.0× | 982 0.6× | 126 | 5.3k | ||
| Ethan Rubinstein Canada | 45 | 1.8k 0.6× | 2.4k 1.1× | 2.4k 1.2× | 1.8k 0.9× | 877 0.5× | 140 | 6.8k | ||
| James J. Rahal United States | 42 | 3.1k 1.1× | 1.8k 0.8× | 2.3k 1.2× | 1.6k 0.9× | 813 0.5× | 109 | 6.5k | ||
| Fé Tubau Spain | 44 | 3.1k 1.0× | 1.1k 0.5× | 2.6k 1.3× | 1.5k 0.8× | 920 0.5× | 173 | 6.1k |
Countries citing papers authored by Douglas J. Biedenbach
Since
Specialization
Citations
This map shows the geographic impact of Douglas J. Biedenbach's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Douglas J. Biedenbach with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Douglas J. Biedenbach more than expected).
Fields of papers citing papers by Douglas J. Biedenbach
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Douglas J. Biedenbach. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Douglas J. Biedenbach. The network helps show where Douglas J. Biedenbach may publish in the future.
Co-authorship network of co-authors of Douglas J. Biedenbach
This figure shows the co-authorship network connecting the top 25 collaborators of Douglas J. Biedenbach. A scholar is included among the top collaborators of Douglas J. Biedenbach based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Douglas J. Biedenbach. Douglas J. Biedenbach is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Hackel, Meredith, Krystyna M. Kazmierczak, Daryl J. Hoban, et al.. (2016). Assessment of the In Vitro Activity of Ceftazidime-Avibactam against Multidrug-Resistant Klebsiella spp. Collected in the INFORM Global Surveillance Study, 2012 to 2014. Antimicrobial Agents and Chemotherapy. 60(8). 4677–4683.
2.
Biedenbach, Douglas J., Robert E. Badal, Mary Motyl, et al.. (2016). In Vitro Activity of Oral Antimicrobial Agents against Pathogens Associated with Community-Acquired Upper Respiratory Tract and Urinary Tract Infections: A Five Country Surveillance Study. Infectious Diseases and Therapy. 5(2). 139–153.
3.
Hackel, Meredith, Robert E. Badal, Samuel K. Bouchillon, Douglas J. Biedenbach, & Daryl J. Hoban. (2015). Resistance Rates of Intra-Abdominal Isolates from Intensive Care Units and Non-Intensive Care Units in the United States: The Study for Monitoring Antimicrobial Resistance Trends 2010–2012. Surgical Infections. 16(3). 298–304.
4.
Hoban, Daryl J., Douglas J. Biedenbach, Daniel F. Sahm, E Reiszner, & Joseph P. Iaconis. (2015). Activity of ceftaroline and comparators against pathogens isolated from skin and soft tissue infections in Latin America – results of AWARE surveillance 2012. The Brazilian Journal of Infectious Diseases. 19(6). 596–603.
5.
Biedenbach, Douglas J., Krystyna M. Kazmierczak, Samuel K. Bouchillon, Daniel F. Sahm, & Patricia A. Bradford. (2015). In Vitro Activity of Aztreonam-Avibactam against a Global Collection of Gram-Negative Pathogens from 2012 and 2013. Antimicrobial Agents and Chemotherapy. 59(7). 4239–4248.
6.
Mendes, Rodrigo E., M.R. Alley, Hélio S. Sader, Douglas J. Biedenbach, & Ronald N. Jones. (2013). Potency and Spectrum of Activity of AN3365, a Novel Boron-Containing Protein Synthesis Inhibitor, Tested against Clinical Isolates of Enterobacteriaceae and Nonfermentative Gram-Negative Bacilli. Antimicrobial Agents and Chemotherapy. 57(6). 2849–2857.
7.
DiPersio, Joseph R., Lalitagauri M. Deshpande, Douglas J. Biedenbach, et al.. (2005). Evolution and dissemination of extended-spectrum β-lactamase-producing Klebsiella pneumoniae: Epidemiology and molecular report from the SENTRY Antimicrobial Surveillance Program (1997–2003). Diagnostic Microbiology and Infectious Disease. 51(1). 1–7.
8.
Jones, Ronald N., et al.. (2003). Validation of commercial dry-form broth microdilution panels for susceptibility testing of AZD2563, a new long-acting oxazolidinone. Clinical Microbiology and Infection. 9(6). 543–546.
9.
Jones, Ronald N., Douglas J. Biedenbach, & Mondell L. Beach. (2003). Influence of patient age on the susceptibility patterns of Streptococcus pneumoniae isolates in North America (2000-2001): report from the SENTRY Antimicrobial Surveillance Program. Diagnostic Microbiology and Infectious Disease. 46(1). 77–80.
10.
Mathai, Dilip, Paul R. Rhomberg, Douglas J. Biedenbach, & Ronald N. Jones. (2002). Evaluation of the in vitro activity of six broad-spectrum β-lactam antimicrobial agents tested against recent clinical isolates from India: a survey of ten medical center laboratories. Diagnostic Microbiology and Infectious Disease. 44(4). 367–377.
11.
Mutnick, Alan H., Douglas J. Biedenbach, John Turnidge, & Ronald N. Jones. (2002). Spectrum and potency evaluation of a new oxazolidinone, linezolid: report from the SENTRY Antimicrobial Surveillance Program, 1998–2000. Diagnostic Microbiology and Infectious Disease. 43(1). 65–73.
12.
Gordon, Kelley A., Mondell L. Beach, Douglas J. Biedenbach, et al.. (2002). Antimicrobial susceptibility patterns of β-hemolytic and viridans group streptococci: report from the SENTRY Antimicrobial Surveillance Program (1997–2000). Diagnostic Microbiology and Infectious Disease. 43(2). 157–162.
13.
Biedenbach, Douglas J. & Ronald N. Jones. (2002). Evaluation of in vitro susceptibility testing criteria for gemifloxacin when tested against Haemophilus influenzae strains with reduced susceptibility to ciprofloxacin and ofloxacin. Diagnostic Microbiology and Infectious Disease. 43(4). 323–326.
14.
Jones, Ronald N., Douglas J. Biedenbach, David M. Johnson, & Michael A. Pfaller. (2001). In VitroEvaluation of BI 397, a Novel Glycopeptide Antimicrobial Agent. Journal of Chemotherapy. 13(3). 244–254.
15.
Biedenbach, Douglas J., Ronald N. Jones, & Michael A. Pfaller. (2001). Activity of BMS284756 against 2,681 recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis: report from The SENTRY Antimicrobial Surveillance Program (2000) in Europe, Canada and the United States. Diagnostic Microbiology and Infectious Disease. 39(4). 245–250.
16.
Biedenbach, Douglas J., et al.. (2001). Comparative antimicrobial activity of ABT-773, a novel ketolide, tested against drug-resistant Gram-positive cocci and Haemophilus influenzae. International Journal of Antimicrobial Agents. 17(6). 451–455.
17.
Jones, Ronald N., Douglas J. Biedenbach, & David M. Johnson. (2000). Cefditoren activity against nearly 1000 non-fastidious bacterial isolates and the development of in vitro susceptibility test methods. Diagnostic Microbiology and Infectious Disease. 37(2). 143–146.
18.
Biedenbach, Douglas J., et al.. (1999). Comparative In Vitro Activity of Gatifloxacin Against Stenotrophomonas maltophilia and Burkholderia Species Isolates Including Evaluation of Disk Diffusion and E Test Methods. European Journal of Clinical Microbiology & Infectious Diseases. 18(6). 428–431.
19.
Biedenbach, Douglas J., Mary S. Barrett, & Ronald N. Jones. (1998). Comparative Antimicrobial Activity and Kill-Curve Investigations of Novel Ketolide Antimicrobial Agents (HMR 3004 and HMR 3647) Tested against Haemophilus influenzae and Moraxella catarrhalis Strains. Diagnostic Microbiology and Infectious Disease. 31(2). 349–353.
20.
Cormican, Martin, Douglas J. Biedenbach, & Ronald N. Jones. (1996). Reevaluation of contemporary laboratory methods for detection of antimicrobial resistance among enterococci. Clinical Microbiology and Infection. 1(3). 190–194.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Stephen G. Jenkins Breakdown of academic impact, for papers by Teresa Spanu Breakdown of academic impact, for papers by Joseph W. Chow Breakdown of academic impact, for papers by Mario Tumbarello Breakdown of academic impact, for papers by David M. Shlaes Breakdown of academic impact, for papers by Romney M. Humphries Breakdown of academic impact, for papers by Philippe Lagacé‐Wiens Breakdown of academic impact, for papers by Ethan Rubinstein Breakdown of academic impact, for papers by James J. Rahal Breakdown of academic impact, for papers by Fé Tubau